A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib Keisuke KidoguchMotoharu ShibusawaTetsuya Tanimoto Clinical trial methodologies 15 July 2021 Pages: 1457 - 1459
Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma Melina MitsiogianniIoannis AnestopoulosMihalis I. Panayiotidis PRECLINICAL STUDIES 08 May 2021 Pages: 1460 - 1468
Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer Xue ZhouXiaowei ZhuNing Wang PRECLINICAL STUDIES 13 May 2021 Pages: 1469 - 1483
Chemoprevention of pancreatic cancer by inhibition of glutathione-S transferase P1 Takahiro KogawaYasushi SatoYoshiro Niitsu Preclinical Studies 24 May 2021 Pages: 1484 - 1492
Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib Jiunn-Chang LinChien-Liang LiuMing-Jen Chen Preclinical Studies 25 May 2021 Pages: 1493 - 1506
Development and validation of a ferroptosis-related prognostic model in pancreatic cancer Chen-jie QiuXue-bing WangWen-tao Gao PRECLINICAL STUDIES 30 June 2021 Pages: 1507 - 1522
Network pharmacology of triptolide in cancer cells: implications for transcription factor binding Ean-Jeong SeoMona DawoodThomas Efferth PRECLINICAL STUDIES Open access 02 July 2021 Pages: 1523 - 1537
IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer Yuefeng HuDong LiuXu Lu PRECLINICAL STUDIES 13 August 2021 Pages: 1538 - 1548
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer Jian ZhangXiaojia WangXichun Hu Phase I Studies Open access 09 June 2021 Pages: 1549 - 1558
Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study Akira KawaiNorifumi NakaToshihiko Doi PHASE I STUDIES Open access 12 June 2021 Pages: 1559 - 1567
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study Yoichi NaitoYasutoshi KubokiTakahiro Kogawa PHASE I STUDIES Open access 23 June 2021 Pages: 1568 - 1576
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors Shivaani KummarApurva K. SrivastavaAlice P. Chen PHASE I STUDIES Open access 28 June 2021 Pages: 1577 - 1586
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors Antoine ItalianoWilson H. Miller JrLillian L. Siu PHASE I STUDIES Open access 28 June 2021 Pages: 1587 - 1597
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases Hiroyasu KanedaKenji SawaTomoya Kawaguchi PHASE I STUDIES 02 July 2021 Pages: 1598 - 1603
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors Crystal S. DenlingerVicki L. KeedyGeoffrey I. Shapiro PHASE I STUDIES Open access 11 July 2021 Pages: 1604 - 1612
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer Christian KollmannsbergerCarolyn D. BrittenAmita Patnaik PHASE I STUDIES 15 July 2021 Pages: 1613 - 1623
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors Bhumsuk KeamChan-Young OckYoung Suk Park PHASE I STUDIES 16 July 2021 Pages: 1624 - 1632
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors Paul N. M. ChengAngela M. LiuFrancis Mussai PHASE I STUDIES 21 July 2021 Pages: 1633 - 1640
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Grégoire MarretNicolas IsambertUNICANCER Head, Neck Group PHASE I STUDIES 28 July 2021 Pages: 1641 - 1648
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study Daisuke KotaniTakayuki YoshinoAkihito Tsuji PHASE II STUDIES Open access 21 May 2021 Pages: 1649 - 1655
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors Ryan AshkarDarren R. FeldmanCostantine Albany Phase II Studies 24 May 2021 Pages: 1656 - 1663
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial M. MegoD. SvetlovskaJ. Mardiak PHASE II STUDIES 29 May 2021 Pages: 1664 - 1670
Serine hydroxymethyltransferase 2: a novel target for human cancer therapy Min XieDong-Sheng Pei Review 03 July 2021 Pages: 1671 - 1681
The biological function of IGF2BPs and their role in tumorigenesis Qiu-Ying DuZhi-Man ZhuDong-Sheng Pei Review 12 July 2021 Pages: 1682 - 1693
Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies Geriletu AoMaria de MiguelEmiliano Calvo REVIEW 21 July 2021 Pages: 1694 - 1701
Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review Yuri ShimadaYuki SatoKeisuke Tomii Short Report 23 May 2021 Pages: 1702 - 1706
Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer Masahide FukudoKei IshibashiMasahiro Kitada Short Report 26 May 2021 Pages: 1707 - 1715
Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis Masaki TakinamiAkira OnoToshiaki Takahashi Short Report Open access 28 May 2021 Pages: 1716 - 1723
Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study Zhichao TianJiaqiang WangWeitao Yao Short Report Open access 22 June 2021 Pages: 1724 - 1731
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis Taichi MiyawakiHirotsugu KenmotsuToshiaki Takahashi Short Report 14 July 2021 Pages: 1732 - 1741